Amgen, Inc. (NASDAQ:AMGN) price target set to $220.00 by Jefferies Financial Group

Analyst Ratings For Amgen, Inc. (NASDAQ:AMGN)

Story continues below

Today, Jefferies Financial Group set its price target on Amgen, Inc. (NASDAQ:AMGN) to $220.00 per share.

There are 12 Hold Ratings, 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amgen, Inc. (NASDAQ:AMGN) is Hold with a consensus target price of $205.4767 per share, a potential 2.57% upside.

Some recent analyst ratings include


    • On 11/29/2018 Cynthia M Patton, SVP, sold 1,777 with an average share price of $202.88 per share and the total transaction amounting to $360,517.76.
    • On 7/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $195.71 per share and the total transaction amounting to $298,457.75.
    • On 6/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $184.27 per share and the total transaction amounting to $281,011.75.
    • On 5/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.10 per share and the total transaction amounting to $265,502.50.
    • On 4/12/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $172.68 per share and the total transaction amounting to $263,337.00.
    • On 3/16/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $189.75 per share and the total transaction amounting to $289,368.75.
    • On 2/14/2018 Sean E. Harper, EVP, sold 1,525 with an average share price of $174.18 per share and the total transaction amounting to $265,624.50.

    About Amgen, Inc. (NASDAQ:AMGN)
    Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

    Recent Trading Activity for Amgen, Inc. (NASDAQ:AMGN)
    Shares of Amgen, Inc. closed the previous trading session at 200,50 −2,43 1,20 % with 205.74 shares trading hands.

    An ad to help with our costs